Insulin Became Weekly. Fewer Injections Make Every Injection Matter More.

For someone using daily basal insulin, treatment can mean an injection every day of the year—before counting any insulin needed with meals.

In 2026, that schedule changed.

The FDA approved two basal insulins designed to be injected once a week:

• Awiqli, or insulin icodec-abae, was approved for adults with type 2 diabetes in March and expanded on October 23 to pediatric patients age 10 and older.
• Onswik, or insulin efsitora alfa-gobe, was approved in September for adults with type 2 diabetes.

Awiqli is now the first once-weekly insulin approved in the United States for children with type 2 diabetes. Onswik is the second weekly option approved for adults. Both are long-acting basal insulins—not GLP-1 drugs, weight-loss treatments or general metabolic-health therapies.

For an eligible patient, the appeal is obvious:

A daily basal schedule can involve 365 injections per year. A weekly schedule involves 52.

That is a genuine reduction in treatment burden.

But weekly insulin is not simply daily insulin with six injections removed. Its extended action changes how quickly a mistake can be corrected, how the medication must be stored and identified, and how clinicians approach transitions, monitoring and illness.

The central tradeoff is simple:

Fewer treatment events may make insulin easier to live with, while making each treatment event more consequential.

What basal insulin does

The body needs insulin between meals and overnight—not only after eating.

In people without diabetes, the pancreas releases a background level of insulin that helps control glucose production by the liver and supports glucose uptake into tissues. Basal insulin therapy attempts to reproduce part of that background signal.

It is different from rapid-acting insulin used around meals.

Once-weekly insulin replaces only the basal component of treatment. It does not necessarily eliminate mealtime insulin for someone who needs it. It also does not eliminate glucose monitoring, follow-up, nutrition planning or individualized clinical decisions.

“One injection a week” therefore does not always mean an entire diabetes regimen has been reduced to one event.

How one injection can last seven days

A weekly insulin must release or express its biological activity slowly enough to cover an entire dosing interval.

The two approved products use different molecular strategies.

Insulin icodec, the active ingredient in Awiqli, binds reversibly to albumin, a common protein in the blood. This creates a circulating reservoir from which active insulin becomes available gradually.

Insulin efsitora, the active ingredient in Onswik, is fused to part of an antibody known as an Fc domain. That design slows its clearance and extends its activity.

The result is a background insulin effect that persists across a week.

That duration is the breakthrough—and the reason weekly insulin requires a different safety mindset.

Once a weekly dose has been administered, it cannot be removed if the wrong product or amount was used, food intake falls unexpectedly or another glucose-lowering treatment increases the risk of hypoglycemia.

What FDA actually approved

The regulatory status is specific to each product and population.

Awiqli

Awiqli is approved as an adjunct to diet and exercise to improve glucose control in adults and pediatric patients age 10 and older with type 2 diabetes.

Its label calls for administration once weekly using its dedicated pen. It is not approved for prediabetes, weight management, longevity or healthy-person glucose optimization.

Onswik

Onswik is approved as an adjunct to diet and exercise for adults with type 2 diabetes.

FDA states that it is not recommended for people with type 1 diabetes because of an increased risk of severe hypoglycemia. Its approval was supported by four randomized, open-label trials comparing weekly efsitora with daily basal insulins.

What was not approved

Neither product is:

• A weight-loss medication
• A substitute for a GLP-1 drug
• A treatment for healthy people
• A performance enhancer
• An anti-aging therapy
• A way to avoid monitoring or clinical follow-up
• Proof that weekly insulin is preferable for every person who needs basal insulin

The innovation is treatment simplification—not metabolic enhancement.

The pediatric approval used a different kind of evidence

The new pediatric indication deserves careful attention because it was not based on a large outcomes trial comparing weekly and daily insulin in hundreds of children.

FDA reports that the pediatric pharmacokinetic study included 18 patients age 10 and older with type 2 diabetes and evaluated a single dose of Awiqli.

The first dose was absorbed more rapidly in the pediatric participants than in adults. Pharmacometric modeling predicted that, after the first few doses, pediatric blood levels would become similar to the levels observed in adults.

FDA therefore concluded that Awiqli was expected to lower glucose in pediatric patients similarly to adults.

This is an example of evidence extrapolation.

It does not mean FDA approved the treatment without evidence. Regulators combined:

• Established adult efficacy data
• The known biology of insulin
• Pediatric pharmacokinetic measurements
• Mathematical exposure modeling
• Existing safety information

But it does mean the pediatric approval provides less direct evidence about long-term real-world use in children than a large, dedicated pediatric outcomes trial would provide.

The study does not independently establish whether weekly insulin improves adherence, quality of life, treatment persistence or long-term glucose control in children. It also cannot precisely quantify rare pediatric safety events.

That distinction should be preserved as use expands.

What the adult trials found

The adult evidence is much larger.

Weekly insulin icodec versus daily glargine

ONWARDS 1 enrolled adults with type 2 diabetes who had not previously used insulin. Participants received either weekly insulin icodec or daily insulin glargine U100.

At 52 weeks, participants using icodec spent:

• 71.9% of time between 70 and 180 mg/dL
• Compared with 66.9% for daily glargine

That difference represented roughly one additional hour per day in the target range.

The hypoglycemia findings were less straightforward.

Clinically significant or severe hypoglycemic events occurred at an estimated rate of:

• 0.30 events per person-year with weekly icodec
• 0.16 events per person-year with daily glargine

At 52 weeks, the estimated difference did not meet the conventional threshold for statistical significance. When extended follow-up was included, the difference did.

The absolute rates were low, but the result cautions against assuming that fewer injections automatically produce less hypoglycemia.

The trial was open-label and funded by the product’s manufacturer.

Weekly efsitora versus daily glargine

QWINT-1 included 795 adults with type 2 diabetes who had not previously used insulin.

After 52 weeks, average A1C changed:

• From 8.20% to 7.05% with weekly efsitora
• From 8.28% to 7.08% with daily glargine

The estimated difference was 0.03 percentage points in favor of efsitora. This established that weekly efsitora was noninferior to daily glargine, but it did not show superiority.

Clinically significant or severe hypoglycemia occurred at rates of:

• 0.50 events per participant-year with efsitora
• 0.88 events per participant-year with glargine

Participants required a median of two efsitora dose adjustments compared with eight glargine adjustments.

That supports a practical advantage: the weekly regimen may reduce not only injection frequency but also repeated titration work.

It does not prove that every weekly insulin causes less hypoglycemia than every daily product. The result came from one specific trial with its own population, dosing structure and comparator.

QWINT-1 was open-label and funded by the product’s manufacturer.

What the broader evidence says

A 2026 systematic review and meta-analysis combined 14 randomized trials involving 8,487 adults with type 2 diabetes.

Compared with daily basal insulin, once-weekly basal insulin was associated with:

• An average A1C reduction approximately 0.09 percentage points greater
• Approximately 1.9 percentage points more time in the target glucose range
• Higher odds of reaching an A1C below 7%
• No statistically significant overall difference in clinically significant or severe hypoglycemia
• A small average increase in weight of approximately 0.34 kilograms

These are modest average differences.

The strongest conclusion is not that weekly insulin controls diabetes dramatically better. It is that weekly insulin generally produced glucose control comparable to daily basal insulin, with small advantages in selected glucose measurements.

Its principal innovation remains convenience.

Why fewer injections could matter

Injection count is only one part of living with diabetes, but it is a visible and repetitive burden.

A weekly basal schedule may be particularly useful for people who:

• Regularly miss daily basal injections
• Experience substantial injection anxiety
• Depend on a caregiver for administration
• Have work or travel schedules that disrupt daily routines
• Find daily treatment reminders emotionally exhausting
• Have delayed starting necessary insulin because of injection burden

Reducing the annual basal-injection schedule from 365 to 52 could make insulin initiation more acceptable.

That benefit should not be dismissed simply because it is difficult to measure with A1C.

But randomized efficacy trials do not yet prove that weekly dosing will produce better adherence in routine care. Trial participants generally receive structured education, monitoring and follow-up that may not resemble everyday practice.

Important unanswered questions include whether weekly insulin produces:

• Fewer missed doses
• Better long-term persistence
• Lower diabetes distress
• Fewer medication errors
• Better quality of life
• Fewer hospitalizations
• Lower total treatment costs
• Better outcomes in patients with lower health literacy or complex caregiving arrangements

Convenience is highly plausible. Its downstream benefits still need to be demonstrated.

The new safety problem: mistakes can last longer

All insulin can cause dangerous hypoglycemia.

Weekly insulin adds a particular concern: one administration error may remain biologically active for several days.

The products are also highly concentrated:

• Awiqli is supplied at 700 units per milliliter
• Onswik is supplied in 500-unit-per-milliliter and 1,000-unit-per-milliliter presentations

Those concentrations are not instructions for patients to calculate injection volumes. The dedicated pens display prescribed units.

FDA labeling warns against transferring Awiqli from its pen into a syringe. The labels also warn about product mix-ups and accidental overdose.

Potential errors include:

• Taking a weekly insulin as though it were daily
• Confusing the pen with another injectable medication
• Repeating a dose because the patient cannot remember whether it was administered
• Using the wrong product or pen
• Attempting a manual concentration conversion
• Making an unsupervised change when food intake, activity, kidney function or another medication changes

Because the insulin remains active for days, hypoglycemia following an overdose may require prolonged monitoring and repeated treatment.

The appropriate response is not to reject weekly insulin. It is to design the workflow around its duration.

A safer weekly workflow

A practical safety system can include:

• One consistent administration day
• Immediate written or electronic confirmation after each injection
• Clear separation from daily or mealtime insulin pens
• Product-specific education from the clinical and pharmacy teams
• No manual concentration conversions
• A defined glucose-monitoring plan
• Ready access to hypoglycemia treatment
• Caregiver education when appropriate
• A clear contact for questions or unexpected glucose readings
• Early clinical review after initiation or transition

For pediatric patients, caregiver coordination becomes especially important. The household needs to know who administers the injection, where it is documented and how duplicate administration will be prevented.

The aim is to make treatment simpler without making it casual.

Weekly insulin does not necessarily adapt quickly to a changing week

Daily life can change faster than a weekly insulin depot.

Food intake may fall during illness. Activity can rise unexpectedly. Kidney function can worsen. Another glucose-lowering medication may be started or increased. Steroid treatment can push glucose sharply upward.

Awiqli’s label notes that, because of its long half-life, changing the weekly dose is not advised merely in response to short-term changes in diet, activity or acute illness. Instead, other parts of the treatment plan may need to be managed under clinical guidance.

This does not mean illness or reduced food intake is unimportant.

It means the patient needs an agreed sick-day and hypoglycemia plan rather than improvising the next weekly injection.

Where weekly insulin fits

Weekly insulin does not erase the broader treatment decision.

For some people with type 2 diabetes, insulin is necessary because glucose levels are very high, symptoms are present or other treatments no longer provide sufficient control.

For others, non-insulin medications may remain preferable because of their effects on weight, cardiovascular risk, kidney disease, hypoglycemia or treatment burden.

The right question is not:

Is weekly insulin better than daily insulin?

It is:

For this particular patient, does reducing injection frequency solve an important problem without creating a larger safety problem?

Someone who reliably takes daily insulin, has frequent short-term changes in intake or is at high risk for hypoglycemia may not gain as much from a weekly formulation.

Someone who repeatedly misses daily injections, depends on a caregiver or is unwilling to start insulin because of injection burden may gain considerably.

What weekly insulin has not been shown to do

The approvals and trials do not establish that weekly insulin:

• Produces weight loss
• Reverses insulin resistance
• Prevents heart attacks better than daily insulin
• Protects the kidneys better than daily insulin
• Extends lifespan
• Treats prediabetes in healthy people
• Improves athletic performance or recovery
• Is safer for every patient
• Eliminates the need for glucose monitoring
• Can be used interchangeably with a GLP-1 medication
• Improves long-term outcomes in children beyond what is predicted from adult data

Insulin has no role as a healthy-person biohack.

Using insulin without an appropriate medical indication can cause profound hypoglycemia, seizure, loss of consciousness or death.

The limits of the evidence

The evidence base is substantial, but important limitations remain:

• Many pivotal trials were open-label.
• Treat-to-target studies provide more monitoring than many patients receive in routine care.
• Trials used different comparators, populations and titration protocols.
• The development programs were manufacturer-funded.
• Most endpoints concerned A1C, time in range and hypoglycemia—not cardiovascular events, kidney failure or survival.
• Long-term real-world data on errors, adherence and persistence are limited.
• There is no direct outcomes trial establishing which weekly product is superior.
• The pediatric expansion relied on adult efficacy evidence, an 18-participant pharmacokinetic study and modeling—not a large pediatric outcomes trial.
• Rare safety events cannot be reliably measured in a pediatric study that small.

None of those limitations makes weekly insulin unimportant.

They define what the approvals have—and have not—established.

The bottom line

Once-weekly basal insulin is a meaningful advance in diabetes treatment.

Awiqli and Onswik can reduce the basal-injection schedule from daily to weekly while delivering glucose control broadly comparable to daily basal insulin in adults with type 2 diabetes.

Awiqli’s pediatric expansion could also reduce treatment burden for children age 10 and older who need basal insulin.

But the breakthrough is convenience—not better health by default.

The evidence shows:

• Weekly insulin can control glucose about as effectively as daily basal insulin.
• Differences in average A1C are small.
• Hypoglycemia remains the central safety concern.
• A dosing error may remain active for days.
• The highly concentrated products require dedicated pens and careful identification.
• Pediatric approval was based partly on extrapolation from adult evidence.
• Long-term real-world adherence and error data are still developing.
• Weekly insulin is not a weight-loss, longevity or performance treatment.

For the right patient, reducing 365 basal injections to 52 could materially improve the experience of treatment.

But the best weekly regimen will not be the one that merely requires fewer injections.

It will be the one built around the fact that every injection matters more.

This article is for general educational purposes and is not medical advice, diagnosis or treatment guidance. Insulin can cause severe, prolonged and potentially fatal hypoglycemia. Starting, stopping, switching or adjusting insulin requires an appropriately qualified prescribing clinician and the product-specific instructions.

Primary sources

1. FDA — Awiqli pediatric approval, October 23, 2026
   FDA Approves First Once-Weekly Insulin for Type 2 Diabetes Mellitus in Pediatric Patients

2. FDA — Awiqli prescribing information
   Full Prescribing Information: insulin icodec-abae

3. FDA — Onswik approval, September 23, 2026
   FDA Approves Once-Weekly Insulin for Type 2 Diabetes Mellitus

4. FDA — Onswik approval letter
   BLA 761408 Approval Letter

5. ONWARDS 1 — insulin icodec versus insulin glargine
   Rosenstock J, et al. N Engl J Med. 2023.
   PubMed PMID 37356066
   ClinicalTrials.gov: NCT04460885

6. QWINT-1 — insulin efsitora versus insulin glargine
   N Engl J Med.
   PubMed PMID 40548694
   ClinicalTrials.gov: NCT05662332

7. Systematic review and meta-analysis of weekly versus daily basal insulin
   Curr Diab Rep. 2026;26:16.
   DOI: 10.1007/s11892-026-01628-3
   PubMed PMID 42277362